Rachel McMinn - 13 Mar 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
Issuer symbol
NGNE
Transactions as of
13 Mar 2024
Net transactions value
$0
Form type
4
Filing time
14 Mar 2024, 20:54:55 UTC
Previous filing
26 Dec 2023
Next filing
25 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGNE Employee Stock Option (Right to buy) Award $0 +93,282 $0.000000 93,282 13 Mar 2024 Common Stock 93,282 $36.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.